An expert opinion on esophageal cancer therapy

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Brown LM, Swanson CA, Gridley G, Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104-9
   PubMed Web of Science ®Google Scholar
• Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7
   PubMed Web of Science ®Google Scholar
• Daly JM, Fry WA, Little AG, Fremgen, esophageal cancer: results of an American college of surgeons patient care evaluation study. J Am Coll Surg 2000;190:562-72; discussion 572-63
   PubMed Web of Science ®Google Scholar
• Gibbs JF, Rajput A, Chadha KS, The changing profile of esophageal cancer presentation and its implication for diagnosis. J Natl Med Assoc 2007;99:620-6
   PubMedGoogle Scholar
• Mariette C, Taillier G, Van Seuningen I, Triboulet JP. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004;78:1177-83
   PubMedGoogle Scholar
• Di Fiore F, Lecleire S, Pop D, Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007;102:2557-63
   PubMed Web of Science ®Google Scholar
• Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953-6
   PubMedGoogle Scholar
• Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31
   PubMed Web of Science ®Google Scholar
• Falk GW. Risk factors for esophageal cancer development. Surg Oncol Clin N Am 2009;18:469-85
   PubMedGoogle Scholar
• Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52
   PubMed Web of Science ®Google Scholar
• Flamen P, Lerut A, Van Cutsem E, Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-10
   PubMed Web of Science ®Google Scholar
• Kato H, Miyazaki T, Nakajima M, The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005;103:148-56
   PubMedGoogle Scholar
• Meltzer CC, Luketich JD, Friedman D, Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000;25:882-7
   PubMed Web of Science ®Google Scholar
• Saltzman JR. Section III: endoscopic and other staging techniques. Semin Thorac Cardiovasc Surg 2003;15:180-6
   PubMedGoogle Scholar
• Puli SR, Reddy JB, Bechtold ML, Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol 2008;14:1479-90
   PubMed Web of Science ®Google Scholar
• van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98:547-57
   PubMed Web of Science ®Google Scholar
• Vilmann P. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of lymph nodes. Gastrointest Endosc 1996;43:S24-9
   PubMedGoogle Scholar
• Hulscher JB, van Sandick JW, de Boer AG, Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-9
   PubMed Web of Science ®Google Scholar
• Omloo JM, Lagarde SM, Hulscher JB, Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007;246:992-1000; discussion 1000-1001
   PubMed Web of Science ®Google Scholar
• Chu KM, Law SY, Fok M, Wong J. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997;174:320-4
   PubMedGoogle Scholar
• Goldminc M, Maddern G, Le Prise E, Oesophagectomy by a transhiatal approach or thoracotomy: a prospective randomized trial. Br J Surg 1993;80:367-70
   PubMed Web of Science ®Google Scholar
• Pennathur A, Zhang J, Chen H, Luketich JD. The ‘best operation’ for esophageal cancer? Ann Thorac Surg 2010;89:S2163-7
   PubMedGoogle Scholar
• Rindani R, Martin CJ, Cox MR. Transhiatal versus Ivor-Lewis oesophagectomy: is there a difference? Aust NZ J Surg 1999;69:187-94
   PubMedGoogle Scholar
• Hulscher JB, Tijssen JG, Obertop H, van Lanschot JJ. Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis. Ann Thorac Surg 2001;72:306-13
   PubMed Web of Science ®Google Scholar
• Peyre CG, Hagen JA, DeMeester SR, Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008;248:979-85
   PubMed Web of Science ®Google Scholar
• Mariette C, Piessen G, Briez N, Triboulet JP. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008;247:365-71
   PubMed Web of Science ®Google Scholar
• Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175:47-51
   PubMed Web of Science ®Google Scholar
• Altorki N, Kent M, Ferrara C, Port J. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002;236:177-83
   PubMed Web of Science ®Google Scholar
• Lerut T, Nafteux P, Moons J, Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004;240:962-72; discussion 972-964
   PubMedGoogle Scholar
• Luketich JD, Alvelo-Rivera M, Buenaventura PO, Minimally invasive esophagectomy: outcomes in 222 patients. Ann Surg 2003;238:486-94; discussion 494-485
   PubMed Web of Science ®Google Scholar
• Luketich J, Pennathur A, Catalano PJ, Results of a phase II multicenter study of minimally invasive esophagectomy (Eastern Cooperative Oncology Group Study E2202), in American Society of Clinical Oncology, Chicago, IL; 2009
   Google Scholar
• Kelsen DP, Winter KA, Gunderson LL, Willett, Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-25
   PubMed Web of Science ®Google Scholar
• Rice TW, Rusch VW, Apperson-Hansen C, Worldwide esophageal cancer collaboration. Dis Esophagus 2009;22:1-8
   PubMed Web of Science ®Google Scholar
• Stein HJ, Feith M, Bruecher BL, Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005;242:566-73; discussion 573-565
   PubMed Web of Science ®Google Scholar
• Altorki NK, Lee PC, Liss Y, Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg 2008;247:434-9
   PubMed Web of Science ®Google Scholar
• Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007;8:545-53
   PubMed Web of Science ®Google Scholar
• Ancona E, Ruol A, Santi S, Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001;91:2165-74
   PubMed Web of Science ®Google Scholar
• Law S, Fok M, Chow S, Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:210-17
   PubMed Web of Science ®Google Scholar
• Maipang T, Vasinanukorn P, Petpichetchian C, Induction chemotherapy in the treatment of patients with carcinoma of the esophagus. J Surg Oncol 1994;56:191-7
   PubMed Web of Science ®Google Scholar
• Nygaard K, Hagen S, Hansen HS, Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992;16:1104-9; discussion 1110
   PubMed Web of Science ®Google Scholar
• Roth JA, Pass HI, Flanagan MM, Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg 1988;96:242-8
   PubMed Web of Science ®Google Scholar
• Schlag PM. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group. Arch Surg 1992;127:1446-50
   PubMedGoogle Scholar
• Cunningham D, Allum WH, Stenning SP, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
   PubMed Web of Science ®Google Scholar
• Kelsen DP, Ginsberg R, Pajak TF, Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-84
   PubMed Web of Science ®Google Scholar
• Allum WH, Stenning SP, Bancewicz J, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062-7
   PubMed Web of Science ®Google Scholar
• Boige V, Pignon J, Saint-Aubert B, Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial, in American Society of Clinical Oncology, Chicago, IL; 2007
   Google Scholar
• Medical Research Council. Surgical resection with or without preoperative chemotherapy in oesophageal cancer. a randomised controlled trial. Lancet 2002;359:1727-33
   PubMedGoogle Scholar
• Thirion PG, Michiels S, Maitre AL, Tierney J. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma, in American Society of Clincial Oncology, Chicago, IL; 2007
   Google Scholar
• Ando N, Iizuka T, Kakegawa T, A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997;114:205-9
   PubMed Web of Science ®Google Scholar
• Pouliquen X, Levard H, Hay JM, 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 1996;223:127-33
   PubMed Web of Science ®Google Scholar
• Ando N, Iizuka T, Ide H, Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol 2003;21:4592-6
   PubMed Web of Science ®Google Scholar
• Arnott SJ, Duncan W, Kerr GR, Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992;24:108-13
   PubMed Web of Science ®Google Scholar
• Gignoux M, Roussel A, Paillot B, The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987;11:426-32
   PubMed Web of Science ®Google Scholar
• Launois B, Delarue D, Campion JP, Kerbaol M. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981;153:690-2
   PubMedGoogle Scholar
• Wang M, Gu XZ, Yin WB, Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989;16:325-7
   PubMed Web of Science ®Google Scholar
• Arnott SJ, Duncan W, Gignoux M, Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005:CD001799
   PubMedGoogle Scholar
• Teniere P, Hay JM, Fingerhut A, Fagniez PL. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991;173:123-30
   PubMedGoogle Scholar
• Fok M, Sham JS, Choy D, Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993;113:138-47
   PubMed Web of Science ®Google Scholar
• Zieren HU, Muller JM, Jacobi CA, Adjuvant postoperative radiation therapy after curative resection of squamous cell carcinoma of the thoracic esophagus: a prospective randomized study. World J Surg 1995;19:444-9
   PubMed Web of Science ®Google Scholar
• Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994;41:391-3
   PubMed Web of Science ®Google Scholar
• Walsh TN, Noonan N, Hollywood D, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7
   PubMed Web of Science ®Google Scholar
• Bosset JF, Gignoux M, Triboulet JP, Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7
   PubMed Web of Science ®Google Scholar
• Urba SG, Orringer MB, Turrisi A, Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13
   PubMed Web of Science ®Google Scholar
• Lee JL, Park SI, Kim SB, A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004;15:947-54
   PubMed Web of Science ®Google Scholar
• Burmeister BH, Smithers BM, Gebski V, Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659-68
   PubMed Web of Science ®Google Scholar
• Tepper J, Krasna MJ, Niedzwiecki D, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92
   PubMed Web of Science ®Google Scholar
• Gaast AV, van Hagen P, Hulshof M, Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study, in American Society of Clinical Oncology, Chicago, IL; 2010
   Google Scholar
• Mariette C, Seitz JF, Maillard E, Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901, in American Society of Clinical Oncology, Chicago, IL; 2010
   Google Scholar
• Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-43
   PubMed Web of Science ®Google Scholar
• Kaklamanos IG, Walker GR, Ferry K, Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-61
   PubMed Web of Science ®Google Scholar
• Fiorica F, Di Bona D, Schepis F, Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30
   PubMed Web of Science ®Google Scholar
• Greer SE, Goodney PP, Sutton JE, Birkmeyer JD. Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 2005;137:172-7
   PubMed Web of Science ®Google Scholar
• Graham AJ, Shrive FM, Ghali WA, Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg 2007;83:1257-64
   PubMedGoogle Scholar
• Jin HL, Zhu H, Ling TS, Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 2009;15:5983-91
   PubMed Web of Science ®Google Scholar
• Gebski V, Burmeister B, Smithers BM, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34
   PubMed Web of Science ®Google Scholar
• Stahl M, Walz MK, Stuschke M, Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-6
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, al-Sarraf M, Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-8
   PubMed Web of Science ®Google Scholar
• al-Sarraf M, Martz K, Herskovic A, Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84
   PubMed Web of Science ®Google Scholar
• Cooper JS, Guo MD, Herskovic A, Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-7
   PubMed Web of Science ®Google Scholar
• Minsky BD, Pajak TF, Ginsberg RJ, INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74
   PubMed Web of Science ®Google Scholar
• Stahl M, Stuschke M, Lehmann N, Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-17
   PubMed Web of Science ®Google Scholar
• Bedenne L, Michel P, Bouche O, Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-8
   PubMed Web of Science ®Google Scholar
• Jouve J, Michel P, Mariette C, Outcome of the nonrandomized patients in the FFCD 9102 trial: chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus, in American Society of Clinical Oncology, Chicago, IL; 2008
   Google Scholar
• Gibson MK, Catalano PJ, Kleinberg L, E2205: a phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus, in American Society of Clinical Oncology, Chicago, IL; 2010
   Google Scholar
• Enzinger PC, Yock T, Suh W, Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer, in Americal Society of Clinical Oncology, Atlanta, GA; 2006
   Google Scholar
• Ruhstaller T, Pless M, Schuller JC, Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06), in American Society of Clinical Oncology, Chicago, IL; 2009
   Google Scholar
• De Vita F, Orditura M, Innocente R, Induction primary CT with Folfox-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC): analysis of preliminary data from B152 Trial, in American Society of Clinical Oncology, Chicago, IL; 2008
   Google Scholar
• Agarwala AK, Hanna N, McCollum A, Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: a pilot study from the Hoosier Oncology Group and the University of Texas Southwestern, American Society of Clinical Oncology, Chicago, IL; 2009
   Google Scholar
• Safran H, Suntharalingam M, Dipetrillo T, Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70:391-5
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Mamon H, Bueno R, Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer, in American Society of Clinical Oncology, Chicago, IL; 2003
   Google Scholar
• Van Cutsem E, Kang Y, Chung H, Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC), in American Society of Clinical Oncology, Chicago, IL; 2009
   Google Scholar
• Bang Y, Chung H, Xu J, Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial, in American Society of Clinical Oncology, Chichago, IL; 2009
   Google Scholar
• Safran H, Dipetrillo T, Akerman P, Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67:405-9
   PubMed Web of Science ®Google Scholar
• Inoue K, Ozeki Y, Suganuma T, Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206-13
   PubMed Web of Science ®Google Scholar
• Kitadai Y, Haruma K, Tokutomi T, Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4:2195-200
   PubMed Web of Science ®Google Scholar
• Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104
   PubMed Web of Science ®Google Scholar
• Ku GY, Ilson DH. Esophagogastric cancer: targeted agents. Cancer Treat Rev 2010;36:235-48
   PubMed Web of Science ®Google Scholar
• Kang Y, Ohtsu A, Cutsem EV, AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC), in American Society of Clinical Oncology, Chicago, IL; 2010
   Google Scholar
• Ilson D, Bains M, Rizk N, Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis, in American Society of Clinical Oncology, Chicago, IL; 2009
   Google Scholar
• Ajani JA. Future developments in esophageal cancer research. Gastroenterol Clin North Am 2009;38:183-8, x
   PubMedGoogle Scholar
• Gillham CM, Lucey JA, Keogan M, (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9
   PubMed Web of Science ®Google Scholar
• Lordick F, Ott K, Krause BJ, PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805
   PubMed Web of Science ®Google Scholar
• Ott K, Gall CV, Lorenzen S, Implementation of a sequential FDG-PET during chemotherapy and early therapy modification in metabolic nonresponders with locally advanced adenocarcinomas of the esophagogastric junction type I and II: experiences from an academic center, in, American Society of Clinical Oncology Gastrointestinal Symposium, Orlando, FL; 2010
   Google Scholar
• Wu X, Gu J, Wu TT, Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006;24:3789-98
   PubMed Web of Science ®Google Scholar
• Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res 2006;12:6565-72
   PubMed Web of Science ®Google Scholar